Six-Year Results from RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

Franck Morschhauser, Loretta Nastoupil, Pierre Feugier, Jean Marc Schiano De Colella, Hervé Tilly, Maria Lia Palomba, Emmanuel Bachy, Christophe Fruchart, Edward N. Libby, Rene Olivier Casasnovas, Ian W. Flinn, Corinne Haioun, Hervé Maisonneuve, Loic Ysebaert, Nancy L. Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Steven Le Gouill, Nicolas DaguindauStéphanie Guidez, Gian Matteo Pica, Alejandro Martín García-Sancho, Armondo López-Guillermo, Jean François Larouche, Kiyoshi Ando, Maria Gomes Da Silva, Marc André, Wu Kalung, Laurie H. Sehn, Koji Izutsu, Guillaume Cartron, Argyrios Gkasiamis, Russell Crowe, Luc Xerri, Nathan H. Fowler, Gilles Salles

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Six-Year Results from RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences